Proportions and Seasonal Patterns of Respiratory Viruses via Rapid Tests in Adults at a Greek Hospital (Oct. 2023-Mar. 2024).
RSV
SARS-CoV-2
adenovirus
epidemiology
influenza A/B
rapid test
respiratory infections
seasonality
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
03 Aug 2024
03 Aug 2024
Historique:
received:
28
06
2024
revised:
31
07
2024
accepted:
02
08
2024
medline:
31
8
2024
pubmed:
31
8
2024
entrez:
29
8
2024
Statut:
epublish
Résumé
Respiratory infections pose a major public health threat. The predominant viruses causing viral respiratory infections are influenza A and B (Flu-A, Flu-B), coronaviruses, respiratory syncytial virus (RSV), and adenovirus. This study aims to investigate the proportion of these cases via rapid antigen tests and assess seasonal patterns. Clinical samples were collected from symptomatic adults presenting to the Emergency and Respiratory Medicine Departments of the University Hospital of Larissa (UHL), Greece from 16 October 2023 to 31 March 2024. Nasal specimens were antigen-tested for Flu-A/B, SARS-CoV-2, RSV, and adenovirus. The total sample of specimens collected was 1434, of which 739 (51.5%) were female and 695 were male (48.5%). The mean age of participants was 57 ± 5.5 years. Among the positive results, we recorded a proportion of 40.18% and 11.40% for influenza A and B, respectively, followed by 35.79% for SARS-CoV-2, 10.70% for RSV, and 1.93% for adenovirus. In Greece, surveillance systems in infection control are underutilized. Rapid tests via multiple antigens can quickly identify viral infections, making them a valuable tool with financial benefits for health systems. Early detection of respiratory infections helps allocate resources efficiently, ensures adequate staff and facilities are available, and improves patient care through refined clinical management.
Sections du résumé
BACKGROUND
BACKGROUND
Respiratory infections pose a major public health threat. The predominant viruses causing viral respiratory infections are influenza A and B (Flu-A, Flu-B), coronaviruses, respiratory syncytial virus (RSV), and adenovirus. This study aims to investigate the proportion of these cases via rapid antigen tests and assess seasonal patterns.
METHODS
METHODS
Clinical samples were collected from symptomatic adults presenting to the Emergency and Respiratory Medicine Departments of the University Hospital of Larissa (UHL), Greece from 16 October 2023 to 31 March 2024. Nasal specimens were antigen-tested for Flu-A/B, SARS-CoV-2, RSV, and adenovirus.
RESULTS
RESULTS
The total sample of specimens collected was 1434, of which 739 (51.5%) were female and 695 were male (48.5%). The mean age of participants was 57 ± 5.5 years. Among the positive results, we recorded a proportion of 40.18% and 11.40% for influenza A and B, respectively, followed by 35.79% for SARS-CoV-2, 10.70% for RSV, and 1.93% for adenovirus.
CONCLUSIONS
CONCLUSIONS
In Greece, surveillance systems in infection control are underutilized. Rapid tests via multiple antigens can quickly identify viral infections, making them a valuable tool with financial benefits for health systems. Early detection of respiratory infections helps allocate resources efficiently, ensures adequate staff and facilities are available, and improves patient care through refined clinical management.
Identifiants
pubmed: 39202015
pii: jpm14080824
doi: 10.3390/jpm14080824
pmc: PMC11355584
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Can Commun Dis Rep. 2021 Mar 31;47(3):132-138
pubmed: 34012336
BMJ Open Respir Res. 2023 Jul;10(1):
pubmed: 37491131
J Clin Virol. 2019 Aug;117:27-32
pubmed: 31158780
Semin Respir Crit Care Med. 2021 Dec;42(6):800-821
pubmed: 34918322
Front Public Health. 2023 Dec 05;11:1298593
pubmed: 38115849
Expert Rev Respir Med. 2022 Mar;16(3):263-272
pubmed: 35245149
MMWR Morb Mortal Wkly Rep. 2021 Jul 23;70(29):1013-1019
pubmed: 34292924
Nature. 2023 May 5;:
pubmed: 37147368
Molecules. 2020 Dec 23;26(1):
pubmed: 33374759
Rev Med Virol. 2021 Jul;31(4):e2189
pubmed: 33156553
Lancet Infect Dis. 2018 Nov;18(11):1191-1210
pubmed: 30243584
MMWR Morb Mortal Wkly Rep. 2023 Apr 07;72(14):355-361
pubmed: 37022977
Int J Environ Res Public Health. 2021 Aug 18;18(16):
pubmed: 34444450
Cureus. 2023 Jul 3;15(7):e41333
pubmed: 37546097
Adv Exp Med Biol. 2020;1279:93-100
pubmed: 32170670
Euro Surveill. 2019 Nov;24(45):
pubmed: 31718741
Antimicrob Resist Infect Control. 2024 Jan 25;13(1):11
pubmed: 38273402
BMJ. 2019 Sep 10;366:l5021
pubmed: 31506273
Influenza Other Respir Viruses. 2021 Mar;15(2):293-314
pubmed: 32997395
Am J Emerg Med. 2022 Apr;54:46-57
pubmed: 35121478
Front Microbiol. 2022 Jun 20;13:908525
pubmed: 35794916
J Clin Med. 2021 Jun 23;10(13):
pubmed: 34201868
Open Forum Infect Dis. 2024 Apr 05;11(5):ofae192
pubmed: 38680614
Diseases. 2023 Sep 15;11(3):
pubmed: 37754318
Sci Rep. 2023 Mar 8;13(1):3886
pubmed: 36890264
Lancet Microbe. 2023 Apr;4(4):e203-e205
pubmed: 36738755
BMC Health Serv Res. 2021 Jul 1;21(1):628
pubmed: 34193124
mBio. 2023 Dec 19;14(6):e0142623
pubmed: 37937979
Semin Respir Crit Care Med. 2016 Aug;37(4):586-602
pubmed: 27486739
MMWR Morb Mortal Wkly Rep. 2017 Oct 06;66(39):1039-1042
pubmed: 28981484